Safety of omalizumab in chronic urticaria during pregnancy : a real-life study
© The Author(s) 2023. Published by Oxford University Press on behalf of British Association of Dermatologists..
BACKGROUND: Managing a pregnant patient with chronic spontaneous urticaria (CSU) is often challenging. Recent data have shown that most CSU treatments in pregnant patients are second-generation H1 antihistamines (sgAHs), while data on the safety of omalizumab are scant.
OBJECTIVES: To evaluate, in a routine clinical practice setting, the efficacy and safety of omalizumab in patients with severe CSU refractory to sgAHs who either became pregnant during treatment or who started the drug during pregnancy.
METHODS: We conducted a retrospective study of women aged ≥ 18 years who were pregnant, who received one or more doses of omalizumab at any time during their pregnancy or who were taking omalizumab at the time of, or in the 8 weeks before, conception.
RESULTS: Twenty-nine pregnant patients were evaluated: 23 (79%) conceived a child while taking omalizumab (group A), while 6 (21%) started omalizumab treatment during pregnancy (group B). Among patients in group A, we observed 23 births (21 liveborn singletons and 1 liveborn twin pair) and 1 miscarriage. Fifteen (65%) patients discontinued omalizumab after confirming their pregnancy, while eight (35%) were exposed to omalizumab during their entire pregnancy. In group B, omalizumab was introduced at a mean (SD) 10.83 (3.60) weeks' gestation and all patients were exposed to it until the end of pregnancy. In this group, there were seven liveborn infants (five singletons and one twin pair). No adverse events, pregnancy complications or congenital anomalies in newborns were recorded in either group.
CONCLUSIONS: Omalizumab for CSU treatment before and during pregnancy does not appear to have negative effects on maternal or fetal outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Clinical and experimental dermatology - 49(2024), 4 vom: 21. März, Seite 344-347 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Patruno, Cataldo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 03.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ced/llad386 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364477458 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364477458 | ||
| 003 | DE-627 | ||
| 005 | 20240403235030.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ced/llad386 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1363.xml |
| 035 | |a (DE-627)NLM364477458 | ||
| 035 | |a (NLM)37956096 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Patruno, Cataldo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety of omalizumab in chronic urticaria during pregnancy |b a real-life study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of British Association of Dermatologists. | ||
| 520 | |a BACKGROUND: Managing a pregnant patient with chronic spontaneous urticaria (CSU) is often challenging. Recent data have shown that most CSU treatments in pregnant patients are second-generation H1 antihistamines (sgAHs), while data on the safety of omalizumab are scant | ||
| 520 | |a OBJECTIVES: To evaluate, in a routine clinical practice setting, the efficacy and safety of omalizumab in patients with severe CSU refractory to sgAHs who either became pregnant during treatment or who started the drug during pregnancy | ||
| 520 | |a METHODS: We conducted a retrospective study of women aged ≥ 18 years who were pregnant, who received one or more doses of omalizumab at any time during their pregnancy or who were taking omalizumab at the time of, or in the 8 weeks before, conception | ||
| 520 | |a RESULTS: Twenty-nine pregnant patients were evaluated: 23 (79%) conceived a child while taking omalizumab (group A), while 6 (21%) started omalizumab treatment during pregnancy (group B). Among patients in group A, we observed 23 births (21 liveborn singletons and 1 liveborn twin pair) and 1 miscarriage. Fifteen (65%) patients discontinued omalizumab after confirming their pregnancy, while eight (35%) were exposed to omalizumab during their entire pregnancy. In group B, omalizumab was introduced at a mean (SD) 10.83 (3.60) weeks' gestation and all patients were exposed to it until the end of pregnancy. In this group, there were seven liveborn infants (five singletons and one twin pair). No adverse events, pregnancy complications or congenital anomalies in newborns were recorded in either group | ||
| 520 | |a CONCLUSIONS: Omalizumab for CSU treatment before and during pregnancy does not appear to have negative effects on maternal or fetal outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anti-Allergic Agents |2 NLM | |
| 650 | 7 | |a Omalizumab |2 NLM | |
| 650 | 7 | |a 2P471X1Z11 |2 NLM | |
| 700 | 1 | |a Guarneri, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Nettis, Eustachio |e verfasserin |4 aut | |
| 700 | 1 | |a Bonzano, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Filippi, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Ribero, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Foti, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Rubegni, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Balato, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Miniello, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Motolese, Alfonso |e verfasserin |4 aut | |
| 700 | 1 | |a Piraccini, Bianca Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Quaglino, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Romita, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Lazzeri, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Buononato, Dario |e verfasserin |4 aut | |
| 700 | 1 | |a Dastoli, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Raia, Flavia |e verfasserin |4 aut | |
| 700 | 1 | |a Napolitano, Maddalena |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental dermatology |d 1993 |g 49(2024), 4 vom: 21. März, Seite 344-347 |w (DE-627)NLM000126810 |x 1365-2230 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2024 |g number:4 |g day:21 |g month:03 |g pages:344-347 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ced/llad386 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2024 |e 4 |b 21 |c 03 |h 344-347 | ||